File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Current treatment strategy for hepatocellular carcinoma

TitleCurrent treatment strategy for hepatocellular carcinoma
Authors
Issue Date2007
PublisherSaudi Arabian Armed Forces Ministry of Defence and Aviation, Medical Services Department. The Journal's web site is located at http://www.smj.org.sa/default.asp
Citation
Saudi Medical Journal, 2007, v. 28 n. 9, p. 1330-1338 How to Cite?
AbstractWith the current practice of surveillance programs in high-risk patients, early stage hepatocellular carcinoma (HCC) is commonly diagnosed. This poses great challenge to clinicians, in terms of prognostic estimation, patient stratification to various treatment modalities and patient management during long-term follow-up. This review focuses on the current trends in the management of HCC, with special attention to tumor staging, treatment algorithm, and outcome of various treatment modalities. According to the American Association for the Study of Liver Diseases (AASLD) practice guideline, Barcelona Clinic Liver Cancer (BCLC) staging system has fulfilled the criteria that HCC patients can be stratified into different prognostic subgroups, to which optimal treatments can be offered. Under this management scheme, curative treatments (hepatic resection, liver transplantation, and percutaneous ablation) would be reserved to the subgroup of patients with relatively good prognosis. For patients with advanced malignancy localized to the liver, local ablation or transarterial chemoembolization (TACE) may offer effective symptomatic palliation, and prolongation of patients' survival. For patients with distant metastases, no effective therapy can be offered, and symptomatic palliative care is the best option. Until now, favorable survival outcomes have been reported following hepatic resection, liver transplantation, and local ablation for HCC. Although the therapeutic effect of TACE is less pronounced than curative treatments, randomized controlled studies have proven its survival benefit for HCC patients. A comprehensive treatment algorithm involving these treatment modalities is mandatory to ensure optimal care of patients with HCC.
Persistent Identifierhttp://hdl.handle.net/10722/83486
ISSN
2015 Impact Factor: 0.562
2015 SCImago Journal Rankings: 0.276
References

 

DC FieldValueLanguage
dc.contributor.authorNg, KKen_HK
dc.contributor.authorPoon, RTPen_HK
dc.date.accessioned2010-09-06T08:41:37Z-
dc.date.available2010-09-06T08:41:37Z-
dc.date.issued2007en_HK
dc.identifier.citationSaudi Medical Journal, 2007, v. 28 n. 9, p. 1330-1338en_HK
dc.identifier.issn0379-5284en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83486-
dc.description.abstractWith the current practice of surveillance programs in high-risk patients, early stage hepatocellular carcinoma (HCC) is commonly diagnosed. This poses great challenge to clinicians, in terms of prognostic estimation, patient stratification to various treatment modalities and patient management during long-term follow-up. This review focuses on the current trends in the management of HCC, with special attention to tumor staging, treatment algorithm, and outcome of various treatment modalities. According to the American Association for the Study of Liver Diseases (AASLD) practice guideline, Barcelona Clinic Liver Cancer (BCLC) staging system has fulfilled the criteria that HCC patients can be stratified into different prognostic subgroups, to which optimal treatments can be offered. Under this management scheme, curative treatments (hepatic resection, liver transplantation, and percutaneous ablation) would be reserved to the subgroup of patients with relatively good prognosis. For patients with advanced malignancy localized to the liver, local ablation or transarterial chemoembolization (TACE) may offer effective symptomatic palliation, and prolongation of patients' survival. For patients with distant metastases, no effective therapy can be offered, and symptomatic palliative care is the best option. Until now, favorable survival outcomes have been reported following hepatic resection, liver transplantation, and local ablation for HCC. Although the therapeutic effect of TACE is less pronounced than curative treatments, randomized controlled studies have proven its survival benefit for HCC patients. A comprehensive treatment algorithm involving these treatment modalities is mandatory to ensure optimal care of patients with HCC.en_HK
dc.languageengen_HK
dc.publisherSaudi Arabian Armed Forces Ministry of Defence and Aviation, Medical Services Department. The Journal's web site is located at http://www.smj.org.sa/default.aspen_HK
dc.relation.ispartofSaudi Medical Journalen_HK
dc.titleCurrent treatment strategy for hepatocellular carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0379-5284&volume=28&issue=9&spage=1330&epage=1338&date=2007&atitle=Current+treatment+strategy+for+hepatocellular+carcinomaen_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.scopuseid_2-s2.0-38849203274en_HK
dc.identifier.hkuros139485en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-38849203274&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume28en_HK
dc.identifier.issue9en_HK
dc.identifier.spage1330en_HK
dc.identifier.epage1338en_HK
dc.publisher.placeSaudi Arabiaen_HK
dc.identifier.scopusauthoridNg, KK=35248894000en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats